Anti-Blood Cancer Compound Library

Cat. No. : CS-L079 (2416 compounds)
Library Contents: PDF | SDF

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2416 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Size (Pre-dissolved DMSO or Solid) Stock Price
30 μL/well (10 mM solution) In-stock Get quote
50 μL/well (10 mM solution) In-stock Get quote
100 μL/well (10 mM solution) In-stock Get quote
250 μL/well (10 mM solution) In-stock Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
* Country or Region:
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
* Phone number:
  Remarks:
 
Please slide the slider!
>>
 
Name, 
Organization name, 
Email address, 
Requested quantity, 
Phone number, 

Request SDF File

x

Please enter your email address. We will send your requested SDF file to you as soon as possible.

  • Data Sheet

  • Description & Advantages

  • Composition

  • Contents

Formulation:A collection of 2416 anti-blood cancer compounds supplied as pre-dissolved Solutions or Solid
Container:96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:-80°C
Shipping:Blue ice

•   A unique collection of 2416 compounds with identified and potential anti-blood cancer activity for high throughput screening (HTS) and high content screening (HCS).

•   Targets include FLT3, Bcr-Abl, JAK, PI3K, PD-1/PD-L1, etc.

•   A useful tool for the discovery of anti-blood cancer drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Detailed compound information with structure, IC50, and brief introduction.

•   Validated NMR and HPLC to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

PDF
Browsing History

    Customize Your Library

    You can select:
    • Specific Compounds
    • Quantities
    • Plate map
    • Concentration
    • Format (Solid or DMSO Solution)

    Please contact us at sales@chemscene.com

    Recommend Products
    CS-L100 Cat. No. : CS-L100

    (126 compounds)

    Tumorigenesis-Related Compound Library

    CS-L010 Cat. No. : CS-L010

    (366 compounds)

    MAPK Compound Library

    CS-L156 Cat. No. : CS-L156

    (414 compounds)

    Autoimmune Disease Compound Library